Connor, Clark & Lunn Investment Management (CC&L)’s Aclaris Therapeutics ACRS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.13M | Sell |
797,134
-67,877
| -8% | -$96.4K | ﹤0.01% | 1015 |
|
|
2025
Q1 | $1.32M | Sell |
865,011
-43,808
| -5% | -$67K | 0.01% | 861 |
|
|
2024
Q4 | $2.25M | Buy |
908,819
+576,413
| +173% | +$1.43M | 0.01% | 695 |
|
|
2024
Q3 | $382K | Buy |
332,406
+216,826
| +188% | +$249K | ﹤0.01% | 1165 |
|
|
2024
Q2 | $127K | Buy |
115,580
+14,807
| +15% | +$16.3K | ﹤0.01% | 1296 |
|
|
2024
Q1 | $125K | Buy |
+100,773
| New | +$125K | ﹤0.01% | 1449 |
|
|
2023
Q4 | – | Sell |
-201,233
| Closed | -$1.38M | – | 1359 |
|
|
2023
Q3 | $1.38M | Sell |
201,233
-9,604
| -5% | -$65.8K | 0.01% | 720 |
|
|
2023
Q2 | $2.19M | Buy |
210,837
+34,187
| +19% | +$355K | 0.01% | 592 |
|
|
2023
Q1 | $1.43M | Buy |
176,650
+159,804
| +949% | +$1.29M | 0.01% | 629 |
|
|
2022
Q4 | $265K | Sell |
16,846
-10,008
| -37% | -$158K | ﹤0.01% | 998 |
|
|
2022
Q3 | $423K | Buy |
+26,854
| New | +$423K | ﹤0.01% | 852 |
|
|
2020
Q4 | – | Sell |
-31,575
| Closed | -$81K | – | 884 |
|
|
2020
Q3 | $81K | Buy |
+31,575
| New | +$81K | ﹤0.01% | 881 |
|